What is Uzedy?
Uzedy is a biosimilar to Mvasi R (bevacizumab) and is indicated for the treatment of certain types of cancer. It is administered intravenously [1].
What is Teva's role with Uzedy?
Teva Pharmaceuticals is involved in the manufacturing and commercialization of Uzedy. In the United States, Uzedy is marketed by Teva Pharmaceuticals [1].
How does Uzedy work?
Uzedy functions by inhibiting vascular endothelial growth factor (VEGF). VEGF is a protein that plays a role in the formation of new blood vessels, which is essential for tumor growth and spread [1]. By blocking VEGF, Uzedy helps to reduce the blood supply to tumors, thereby slowing or stopping their growth.
What conditions can Uzedy treat?
Uzedy is approved for the treatment of specific cancers, including metastatic colorectal cancer, glioblastoma multiforme, and non-small cell lung cancer. It is also used for certain types of cervical cancer and ovarian cancer [1].
When can Uzedy's patent expire?
The patent expiration for Uzedy, as with other biosimilars, is tied to the patents of the reference product, Mvasi R (bevacizumab). Information on specific patent expiry dates for biosimilars and their reference products can be found on specialized databases. DrugPatentWatch.com provides detailed information on drug patents and exclusivity periods [2].
Who are Uzedy's competitors?
Uzedy competes in the biosimilar market for bevacizumab. Other biosimilars to bevacizumab, such as Mvasi R itself (as it can be manufactured by different companies) and other independently developed bevacizumab biosimilars, are also available or in development. The competitive landscape is influenced by regulatory approvals and market exclusivity [2].